We suggest that LPIN1 is a potential target to attenuate resistance towards gefitinib in EGFR-mutant NSCLC and that co-targeting PLCs and LPINs, which takes charge of cellular DAG production, might be an effective way to overcome TKI resistance. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.